Large studies have been performed to test mTOR inhibitors against cancer.The combination of mTOR inhibitors with hormone- or HER2-targeted therapies appears to be a promising strategy for overcoming resistant disease and preventing the development of resistance[40]–[41]. Here, ERBB2 is linked to cancer.